Liefferinckx C - Search Results

1

Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases.

Liefferinckx C, Bottieau J, Toubeau JF, Thomas D, Rahier JF, Louis E, Baert F, Dewint P, Pouillon L, Lambrecht G, Vallée F, Vermeire S, Bossuyt P, Franchimont D. Liefferinckx C, et al. Inflamm Bowel Dis. 2022 Feb 1;28(2):208-217. doi: 10.1093/ibd/izab042. Inflamm Bowel Dis. 2022. PMID: 33783494

2

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

Liefferinckx C, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. Liefferinckx C, et al. Inflamm Bowel Dis. 2017 Aug;23(8):1371-1381. doi: 10.1097/MIB.0000000000001120. Inflamm Bowel Dis. 2017. PMID: 28498153

3

Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn's Disease.

Amininejad L, Charloteaux B, Theatre E, Liefferinckx C, Dmitrieva J, Hayard P, Muls V, Maisin JM, Schapira M, Ghislain JM, Closset P, Talib M, Abramowicz M, Momozawa Y, Deffontaine V, Crins F, Mni M, Karim L, Cambisano N, Ornemese S, Zucchi A, Minsart C, Deviere J, Hugot JP, De Vos M, Louis E, Vermeire S, Van Gossum A, Coppieters W, Twizere JC, Georges M, Franchimont D; International IBD Genetics Consortium. Amininejad L, et al. Among authors: liefferinckx c. Gastroenterology. 2018 Jun;154(8):2165-2177. doi: 10.1053/j.gastro.2018.02.028. Epub 2018 Mar 6. Gastroenterology. 2018. PMID: 29501442

4

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).

Franchimont D, Ferrante M, Louis E, De Vos M, Dewit O, Van Hootegem P, Moreels T, Liefferinckx C, Bossuyt P, Baert F, Rahier JF, Vermeire S. Franchimont D, et al. Among authors: liefferinckx c. Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):49-53. Acta Gastroenterol Belg. 2018. PMID: 29562378 Free article. No abstract available.

5

Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases.

Liefferinckx C, Franchimont D. Liefferinckx C, et al. Inflamm Bowel Dis. 2018 Jun 8;24(7):1428-1439. doi: 10.1093/ibd/izy109. Inflamm Bowel Dis. 2018. PMID: 29788122 Review.

6

Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.

Liefferinckx C, Minsart C, Cremer A, Amininejad L, Tafciu V, Quertinmont E, Tops S, Devière J, Gils A, van Gossum A, Franchimont D. Liefferinckx C, et al. Eur J Gastroenterol Hepatol. 2019 Apr;31(4):478-485. doi: 10.1097/MEG.0000000000001356. Eur J Gastroenterol Hepatol. 2019. PMID: 30672828

7

Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study.

Cremer A, Ku J, Amininejad L, Bouvry MR, Brohet F, Liefferinckx C, Devière J, van Gossum A, Smet J, Stordeur P, Franchimont D. Cremer A, et al. Among authors: liefferinckx c. J Crohns Colitis. 2019 Oct 28;13(11):1372-1379. doi: 10.1093/ecco-jcc/jjz069. J Crohns Colitis. 2019. PMID: 30944925

8

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.

Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, De Vos M, Van Moerkercke W, Rahier JF, Bossuyt P, Dutré J, Humblet E, Staessen D, Peeters H, Van Hootegem P, Louis E, Franchimont D, Baert F, Vermeire S; Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group]. Liefferinckx C, et al. J Crohns Colitis. 2019 Oct 28;13(11):1401-1409. doi: 10.1093/ecco-jcc/jjz080. J Crohns Colitis. 2019. PMID: 30989232 Free article.

9

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D. Liefferinckx C, et al. United European Gastroenterol J. 2019 Jul;7(6):750-758. doi: 10.1177/2050640619841538. Epub 2019 Mar 24. United European Gastroenterol J. 2019. PMID: 31316779 Free PMC article.

10

Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.

Kopylov U, Hanzel J, Liefferinckx C, De Marco D, Imperatore N, Plevris N, Baston-Rey I, Harris RJ, Truyens M, Domislovic V, Vavricka S, Biemans V, Myers S, Sebastian S, Ben-Horin S, González Lama Y, Gilletta C, Ariella BS, Zelinkova Z, Weisshof R, Storan D, Zittan E, Farkas K, Molnar T, Franchimont D, Cremer A, Afif W, Castiglione F, Lees C, Barreiro-de Acosta M, Lobaton T, Doherty G, Krznaric Z, Pierik M, Hoentjen F, Drobne D. Kopylov U, et al. Among authors: liefferinckx c. Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. doi: 10.1111/apt.15784. Epub 2020 May 15. Aliment Pharmacol Ther. 2020. PMID: 32412134

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page